𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis B virus–specific CD4 T cell immunity after liver transplantation for chronic hepatitis B

✍ Scribed by Ying Luo; Chung Mau Lo; Cindy K. Cheung; George K. Lau; John Wong


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
140 KB
Volume
15
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


Cellular immunity plays an important role in the long-term control of hepatitis B virus (HBV) infection. We studied the changes in HBV-specific CD4 T cell immunity after orthotopic liver transplantation (OLT) for chronic hepatitis B under antiviral prophylaxis. T cell proliferation and interferon-␥ production in response to in vitro challenge with HBV-encoded antigens were tested in 40 OLT recipients without HBV recurrence and in 12 OLT recipients with HBV recurrence more than 1 year after transplantation, and they were compared to 40 subjects with chronic HBV infection and to 23 subjects with self-limited HBV infection. The frequency and magnitude of the HBV-specific CD4 T cell response were significantly lower in 40 OLT recipients with HBV clearance, but the T cell reactivity to mitogen (phytohemagglutinin) and recall antigen (tetanus toxoid) was maintained. In the 12 OLT recipients with HBV recurrence, however, the HBV-specific T cell immunity was enhanced to a level comparable to that of patients with chronic hepatitis B, and the level was dependent on the serum viral load. In conclusion, HBV-specific CD4 T cell immunity is antigen-driven and evanesces with viral clearance, hence providing a favorable milieu for reactivation once prophylaxis is withdrawn. The cellular immunity in recipients with recurrence is not significantly different from that of individuals with chronic hepatitis B.


📜 SIMILAR VOLUMES


Hepatitis B virus cellular immunity afte
✍ Anne Marie Roque-Afonso 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 1 views

Chronic hepatitis B virus (HBV) infection is a common cause of advanced liver disease and hepatocellular carcinoma and has become a worldwide public health issue. Liver transplantation (LT) is the most effective therapeutic option for HBV-infected patients who have acute or chronic liver failure and

Sustained and focused hepatitis B virus
✍ Florian Bihl; Elisabetta Loggi; John V. Chisholm III; Maurizio Biselli; Maria C. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 1 views

Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is associated with poor graft-and patientsurvival. Treatment with HBV-specific immunoglobulins (HBIG) in combination with nucleos(t)ide analogs is effective in preventing HBV reinfection of the graft and improving OLT ou

Spontaneous clearance of chronic hepatit
✍ P. V. Suneetha; Ingmar Mederacke; Albert Heim; Murat Bastürk; Markus Cornberg; C 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

et al., 1 published in the January issue of Liver Transplantation, describing 2 cases of spontaneously cleared hepatitis C virus (HCV) infection in human immunodeficiency virus-coinfected patients early after liver transplantation. The cause for HCV clearance in those cases remained unclear. We rece

Hepatitis B virus with antigenically alt
✍ Ulrike Protzer-Knolle; Uta Naumann; Ralph Bartenschlager; Thomas Berg; Uwe Hopf; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 2 views

"Escape" variants of hepatitis B virus (HBV) can cause infection despite previous immunization. These viruses show alterations of the immunogenic major hydrophilic loop of the HBV small surface protein (s-protein). We studied whether HBV "escape" variants were selected in patients with graft infecti

Intramuscular hepatitis B immune globuli
✍ Yao, Francis Y. ;Osorio, Robert W. ;Roberts, John P. ;Poordad, Fred F. ;Briceno, 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 59 KB

Immunoprophylaxis using intravenous (IV) hepatitis B immune globulin (HBIG) decreases the recurrence of hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). However, IV HBIG is expensive, has significant side effects, and is inconvenient to administer. An alternative appro